Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy.

This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects.

As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy.

This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects.

As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy.

This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects.

As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy.

This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects.

As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy.

This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects.

As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy.

This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects.

As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy.

This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects.

As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy.

This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects.

As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration. This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated. The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).